StockNews.com initiated coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Free Report) in a report issued on Saturday. The brokerage issued a hold rating on the biotechnology company’s stock.
Nabriva Therapeutics Price Performance
The company has a debt-to-equity ratio of 0.12, a current ratio of 0.85 and a quick ratio of 0.52. The stock has a market cap of $45.46 million, a PE ratio of -0.07 and a beta of 1.53. Nabriva Therapeutics has a 52-week low of $1.22 and a 52-week high of $8.45.
Nabriva Therapeutics Company Profile
Featured Articles
- Five stocks we like better than Nabriva Therapeutics
- Why Invest in 5G? How to Invest in 5G Stocks
- Dow Jones: A Relevant Benchmark or a Relic of the Past?
- How Investors Can Find the Best Cheap Dividend Stocks
- 3 Big-Name Stocks Just Announced Big-Time Dividend Increases
- Are Penny Stocks a Good Fit for Your Portfolio?
- Market Overreaction: 2 Stocks to Buy on the Way Down
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.